<DOC>
	<DOCNO>NCT00002651</DOCNO>
	<brief_summary>RATIONALE : Testosterone stimulate growth prostate cancer cell . Hormone therapy may effective treatment prostate cancer . It yet know regimen hormone therapy effective stage IV prostate cancer . PURPOSE : This randomized phase III trial study two different regimen hormone therapy compare well work treat men stage IV prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Treating Men With Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient metastatic stage IV prostate cancer responsive combine androgen-deprivation therapy ( CAD ) treat intermittent vs continuous CAD . - Compare effect treatment regimens impotence , libido , vitality/fatigue well physical emotional well-being patient . Secondary - Compare general symptom , role functioning , global perception quality life , social functioning patient treat regimen . - Assess prostate-specific antigen ( PSA ) level continuous CAD administer randomization evaluate PSA change throughout randomized treatment patient . OUTLINE : This randomize , multicenter study . Patients stratify accord SWOG performance status ( 0-1 v 2 ) , severity disease ( minimal v extensive ) , prior hormonal therapy ( neoadjuvant hormonal therapy v finasteride v neither ) . - Induction therapy : Patients receive combine androgen-deprivation ( CAD ) therapy comprise goserelin subcutaneously month oral bicalutamide daily 8 course ( 7 month ) . - Consolidation therapy : Patients randomize 1 2 consolidation regimen . - Arm I ( continuous CAD therapy ) : Patients continue CAD therapy induction therapy . Treatment continue absence disease progression . - Arm II ( intermittent CAD therapy ) : Patients undergo observation absence rise prostate-specific antigen ( PSA ) clinical symptom progressive disease . Patients rise PSA progressive disease begin CAD therapy induction therapy . Patients whose PSA normalize 8 course return observation . Patients whose PSA normalize 8 course continue CAD therapy . Quality life assess induction therapy , 3 month ( consolidation therapy ) , 9 15 month . Patients follow every 6-12 month least 10 year . PROJECTED ACCRUAL : Approximately 1,500 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Metastatic stage IV ( stage D2 ) Any number bone metastases bone scan allow Unequivocal visceral organ metastasis ( liver , brain , lung ) allow No suspect second primary tumor unless metastasis histologically confirm , include special stain ( e.g. , prostate specific antigen [ PSA ] prostatic alkaline phosphatase [ PAP ] ) For entry late induction therapy : No 1 month begin antiandrogen therapy begin luteinizing hormonereleasing hormone ( LHRH ) agonist therapy No 6 month since initiation current combine androgendeprivation therapy ( LHRH agonist antiandrogen ) The effectiveness current depot LHRH agonist would extend beyond 8 month initiation combine androgen therapy PSA least 5 ng/mL No acute spinal cord compression PATIENT CHARACTERISTICS : Age : Adult Performance status : SWOG 02 Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Recovered major infection No active medical illness would preclude study limit survival No malignancy within past 5 year except : Adequately treat basal cell squamous cell skin cancer Adequately treat carcinoma situ bladder Adequately treat superficial cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biological response modifier therapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : See Disease Characteristics More 1 year since prior neoadjuvant adjuvant hormonal therapy duration 4 month Single combination therapy allow More 1 year since prior finasteride prostate cancer duration 9 month ( less 6 month benign prostatic hypertrophy ) Prior concurrent megestrol hot flash allow No concurrent hormonal therapy Radiotherapy : No concurrent radiotherapy palliation painful bone metastases Surgery : No prior bilateral orchiectomy Recovered prior major surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>